Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615833 | 1.00 | ADRA1A (0.47) | ADRA1AKDM4EMAPK1HIF1APAOX | |
| SCHEMBL12019226 | 0.91 | ADRA1A (0.42) | ADRA1AKDM4EMAPK1HIF1APAOX | |
| SCHEMBL18510169 | 0.88 | KDM4E (0.35) | ADRA1AKDM4EMAPK1HIF1ASMN1; SMN2 | |
| SCHEMBL18510168 | 0.88 | KDM4E (0.35) | ADRA1AKDM4EMAPK1HIF1ASMN1; SMN2 | |
| SCHEMBL21081927 | 0.88 | KDM4E (0.35) | ADRA1AKDM4EMAPK1HIF1ASMN1; SMN2 | |
| SCHEMBL17168743 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTNAMPTEPHX2 | |
| SCHEMBL5492139 | 0.87 | SMN1; SMN2 (0.38) | ADRA1AMAPK1SMN1; SMN2HPGDHTT | |
| SCHEMBL20999873 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTNAMPTEPHX2 | |
| SCHEMBL17767812 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTNAMPTEPHX2 | |
| SCHEMBL26382038 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTNAMPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159547-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20170016050-A1 | NOVEL AZO COMPOUND, USE THEREOF AND METHOD FOR PREPARING SAME | BIONEER CORPORATION (KR) | 2017-01-19 | — | — | US | disclosed |
| US-9448231-B2 | Application of quantum dots for nuclear staining | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9440988-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2016-09-13 | — | — | US | disclosed |
| US-8535881-B2 | High speed parallel molecular nucleic acid sequencing | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-09-17 | — | — | US | disclosed |
| US-8298513-B2 | Hexatriene-β-carbonyl compound | OSAKA UNIVERSITY (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8298513-B2 | Hexatriene-β-carbonyl compound | OSAKA UNIVERSITY (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120219948-A1 | APPLICATION OF QUANTUM DOTS FOR NUCLEAR STAINING | VENTANA MEDICAL SYSTEMS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | BEACHY PHILIP A (US) | 2012-05-31 | — | — | US | disclosed |
| US-20100008857-A1 | NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND | OSAKA UNIVERSITY (JP) | 2010-01-14 | — | — | US | disclosed |
| WO-2009140683-A1 | LIVING COPOLYMER PROTEIN/PEPTIDE HYBRIDS FOR BIOMEDICAL APPLICATIONS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090263868-A1 | Nucleotide Compositions Comprising Photocleavable Markers And Methods Of Preparation Thereof | AMBERGEN, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090156825-A1 | Fluorescent compounds that bind to histone deacetylase | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| US-7547530-B2 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | AMBERGEN, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH AACHEN (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH AACHEN (DE) | 2009-01-15 | — | — | US | disclosed |
| US-7423122-B2 | N-terminal and C-terminal markers in nascent proteins | AMBERGEN, INC. | 2008-09-09 | — | — | US | disclosed |
| US-7312060-B2 | Methods for the detection, analysis and isolation of nascent proteins | AMBERGEN, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070003936-A1 | Methods for the detection of colorectal cancer | AMBERGEN, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159547-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | CD209, MRPL9, RXFP1 | ADRA1A 1509/4885KDM4E 2718/4885MAPK1 956/4885 |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | ADRA1A 4803/4885KDM4E 1013/4885MAPK1 2370/4885 |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | ADRA1A 4275/4885KDM4E 2196/4885MAPK1 4299/4885 |
| US-20090156825-A1 | Fluorescent compounds that bind to histone deacetylase | HDAC1, HDAC3, HDAC11 | ADRA1A 3760/4885KDM4E 251/4885MAPK1 3639/4885 |
| US-20120219948-A1 | APPLICATION OF QUANTUM DOTS FOR NUCLEAR STAINING | DNASE1, DNASE1L3, MKI67 | ADRA1A 4843/4885KDM4E 2654/4885MAPK1 3392/4885 |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | BHMT2, MSRB3, PRMT3 | ADRA1A 2700/4885KDM4E 1575/4885MAPK1 3451/4885 |
| US-20090263868-A1 | Nucleotide Compositions Comprising Photocleavable Markers And Methods Of Preparation Thereof | POLN, NT5C3B, RNGTT | ADRA1A 4700/4885KDM4E 4775/4885MAPK1 4003/4885 |
| US-20100008857-A1 | NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND | CBR1, CBR3, DCXR | ADRA1A 321/4885KDM4E 1236/4885MAPK1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.